1 reports of this reaction
3.2% of all INFLUENZINUM reports
#8 most reported adverse reaction
DYSPHONIA is the #8 most commonly reported adverse reaction for INFLUENZINUM, manufactured by Boiron. There are 1 FDA adverse event reports linking INFLUENZINUM to DYSPHONIA. This represents approximately 3.2% of all 31 adverse event reports for this drug.
Patients taking INFLUENZINUM who experience dysphonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPHONIA is moderately reported among INFLUENZINUM users, representing a notable but not dominant share of adverse events.
In addition to dysphonia, the following adverse reactions have been reported for INFLUENZINUM:
The following drugs have also been linked to dysphonia in FDA adverse event reports:
DYSPHONIA has been reported as an adverse event in 1 FDA reports for INFLUENZINUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPHONIA accounts for approximately 3.2% of all adverse event reports for INFLUENZINUM, making it a notable side effect.
If you experience dysphonia while taking INFLUENZINUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.